·药物研究动态·

　　纪立农

　　作者单位：100044北京，北京大学人民医院

　　【提要】德谷胰岛素是新一代基础胰岛素类似物，通过经皮下注射后形成多六聚体，从而发挥超长效(>24h)作用。德谷胰岛素具有平坦的药代动力学曲线。相较于目前临床使用的基础胰岛素类似物能够更平稳的实现对血糖的控制。临床研究结果显示，德谷胰岛素在有效控制血糖的同时，还降低了治疗中的个体变异性及低血糖事件的发生。

　　【关键词】德谷胰岛素;糖尿病;超长效基础胰岛素类似物

　　doi:10.3969/j.issn.1006-6187.2011.08.024

　　Insulin degluderc: A new generation of ultra-long-acting basal insulin analogue

　　JI Li-nong. Department Endocrinology, Peking Univercity Beijing People\'s Hospital, Beijing 100044, China

　　【Summary】Insulin degludec (IDeg) is a new generation of ultra-long-acting basal insulin analogue. The IDeg monomers are released slowly from soluble multi-haxamers formed after subcutaneous injection, resulting in an ultra-long effect (half-life of IDeg > 24h) and a smooth and stable pharmacokinetic profile at steady state. These attributes are expected to provide an improved glycaemic control and to lower the risk of hypoglycaemia as compared with currently available basal insulin analogs. In the clinical exploratory phase 1 and 2 trials in patients with T1DM/T2DM, insulin degludec is safe and well tolerated, less variable and more stable in glycaemic control with reduced rates of hypoglycaemia.

　　【Key words】Insulin degludec; Diabetes; Ultra-long-acting basal insulin analogue